Fig. 1: Clinical response to combination therapy aimed at overcoming fusion-mediated drug resistance.
From: Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors
a EGFR L858R mutant adenocarcinoma acquired ALK fusion. Combination of erlotinib and alectinib evoked a response in lung and brain lesions. b Combined use of osimertinib and trametinib successfully shrank the EGFR exon 19 deletion (del19) lung adenocarcinoma, which had acquired an ESYT2-BRAF fusion. c Positron emission tomography (PET)-CT images show the progression of EGFR del19 adenocarcinoma with a putative GKAP1-NTRK2 fusion following treatment with osimertinib plus larotrectinib.
